BIIB Biogen Inc.

Biogen to Present at the 2017 RBC Capital Markets Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the 2017 RBC Capital Markets Global Healthcare Conference. The webcast will be live on Wednesday, February 22, 2017 at 3:05 p.m. EST. To access the live webcast, please visit Biogen’s Investors section at www.biogen.com/investors. An archived version of the webcast will be available following the presentation.

About Biogen

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). Building on its heritage in biologics, Biogen also manufactures and commercializes high-quality biosimilars. For more information, please visit www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook, YouTube.

EN
15/02/2017

Underlying

BIIBBiogen Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biogen Inc.

 PRESS RELEASE
Free
BIIB BIOGEN INC.

Biogen and Stoke Therapeutics Announce Presentations of Clinical Data ...

Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress – 3-year data from open-label extension (OLE) studies demonstrate the potential for disease modification with durable seizure reductions and improvements in cognition and behavior on top of standard anti-seizure medicines – – Substantial improvement in overall seizure burden and seizure free days observed with ongoing treatment – CAMBRIDGE, Mass. and BEDFORD, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- ...

August 25, 2025 1 EN
 PRESS RELEASE
Free
BIIB BIOGEN INC.

Austria and Germany to become the first markets in the European Union ...

Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab) TOKYO and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the anti-amyloid beta (Aβ) monoclonal antibody “LEQEMBI®” has been launched in Austria on August 25, 2025 and will be launched in Germany on September 1, 2025. LEQEMBI received the European Commission (EC) approval in ...

August 25, 2025 1 EN
David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Yun Zhong
BIIB BIOGEN INC.
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
TLX TELIX PHARMACEUTICALS LIMITED
08/22/25 August 22, 2025 1 EN
Laura Chico
  • Laura Chico
XENE XENON PHARMACEUTICALS INC
NBIX NEUROCRINE BIOSCIENCES INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
STOK STOKE THERAPEUTICS
EWTX EDGEWISE THERAPEUTICS INC
08/22/25 August 22, 2025 1 EN
Laura Chico
  • Laura Chico
XENE XENON PHARMACEUTICALS INC
NBIX NEUROCRINE BIOSCIENCES INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
STOK STOKE THERAPEUTICS
EWTX EDGEWISE THERAPEUTICS INC
08/15/25 August 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch